Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03281538 · ClinicalTrials.gov registry record · Phase 3
Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
A Phase 3 study of Uremic Pruritus, sponsored by Cara Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 288
- Enrollment target
- 20
- Study locations
NCT03281538 is a Phase 3 study of Uremic Pruritus that has completed, run by Cara Therapeutics. The registered enrollment target is 288 participants. The trial reports 20 study locations across 12 states.
The verdict
NCT03281538, a Phase 3 study of Uremic Pruritus, has completed, sponsored by Cara Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 288 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open-label multicenter, long-term extension safety study to evaluate the safety of IV CR845 administered after each dialysis session over a Treatment Period of up to 52 weeks.
Conditions Studied
Interventions
- DRUG CR845
Study Locations (20)
California
- Cara Therapeutics Study Site - Chula Vista
- Cara Therapeutics Study Site - El Centro
- Cara Therapeutics Study Site - Long Beach
- Cara Therapeutics Study Site - Northridge
Florida
- Cara Therapeutics Study Site - Hollywood
- Cara Therapeutics Study Site - Tampa
- Cara Therapeutics Study Site - Winter Park
Georgia
- Cara Therapeutics Study Site - Albany
- Cara Therapeutics Study Site - Augusta
New Mexico
- Cara Therapeutics Study Site - Albuquerque
- Cara Therapeutics Study Site - Gallup
New York
- Cara Therapeutics Study Site - Mineola
- Cara Therapeutics Study Site - Ridgewood
Colorado
- Cara Therapeutics Study Site - Denver
Idaho
- Cara Therapeutics Study Site - Meridian
Massachusetts
- Cara Therapeutics Study Site - Springfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 288 participants |
| Start Date | 2017-08-14 |
| Est. Completion | 2020-02-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03281538
The ClinicalTrials.gov registry entry for NCT03281538 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 288 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cara Therapeutics, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Uremic Pruritus appearing as the primary indexed condition, and to 1 intervention - of which CR845 is the first listed.
NCT03281538 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT03281538 about?
NCT03281538 is a clinical study titled "Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus". This is an open-label multicenter, long-term extension safety study to evaluate the safety of IV CR845 administered after each dialysis session over a Treatment Period of up to 52 weeks.
What is the current status of trial NCT03281538?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 288 participants. The study started on 2017-08-14. Estimated completion is 2020-02-11.
What conditions does trial NCT03281538 study?
This clinical trial studies the following conditions: Uremic Pruritus.
What interventions are being tested in trial NCT03281538?
The interventions under investigation include: CR845 (DRUG).
Who is sponsoring clinical trial NCT03281538?
This trial is sponsored by Cara Therapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03281538 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uremic Pruritus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.